Literature DB >> 7665723

Disposition of gabapentin in anuric subjects on hemodialysis.

M O Wong1, M A Eldon, W F Keane, D Türck, H N Bockbrader, B A Underwood, A J Sedman, C E Halstenson.   

Abstract

Gabapentin is an anticonvulsant drug, which in man is cleared solely by renal excretion and is not bound to plasma proteins. Because the clearance of gabapentin is dependent on renal function, the pharmacokinetics of gabapentin were investigated in anuric subjects maintained on hemodialysis. Plasma samples were obtained over an 8-day period after administration of single oral 400-mg doses of gabapentin. Pre- and post-dialyzer plasma samples and dialysate samples from quantitative collection of dialyzer effluent were obtained during hemodialysis sessions performed 2, 4, and 7 days after dosing. A mean (SD) maximum gabapentin plasma concentration of 6.0 (2.4) micrograms/mL was achieved at 4.7 (2.1) hours post-dose. The elimination half-life of gabapentin on non-hemodialysis days averaged 132 hours. Approximately 35% of the gabapentin dose was recovered in dialysate, and mean hemodialysis clearance of gabapentin was 142 (26) mL/min; approximately 93% of the dialyzer creatinine clearance. Gabapentin elimination half-life during hemodialysis was approximately 4 hours. Systemic plasma gabapentin concentrations increased approximately 30% during the first 2 hours after hemodialysis as a result of drug redistribution in the body. It is recommended that patients with end-stage renal disease maintained on hemodialysis receive an initial 300-mg to 400-mg gabapentin loading dose. Plasma gabapentin concentrations can be maintained by giving 200 to 300 mg of gabapentin after every 4 hours of hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665723     DOI: 10.1002/j.1552-4604.1995.tb05020.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

Review 1.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

2.  71-year-old man with chronic kidney failure and sudden change of mental status.

Authors:  Aaron S Mansfield; Qi Qian
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

3.  Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia.

Authors:  T Y Hung; V K Seow; C F Chong; T L Wang; C C Chen
Journal:  BMJ Case Rep       Date:  2009-05-10

4.  Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.

Authors:  Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen
Journal:  J Am Soc Nephrol       Date:  2018-06-05       Impact factor: 10.121

5.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

Review 6.  The management of diabetic neuropathy in CKD.

Authors:  Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

Review 7.  Gabapentin: in postherpetic neuralgia.

Authors:  Monique P Curran; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease.

Authors:  Flaminia Coluzzi
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 9.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Pain management in patients with chronic kidney disease and end-stage kidney disease.

Authors:  Payel J Roy; Melanie Weltman; Laura M Dember; Jane Liebschutz; Manisha Jhamb
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-11       Impact factor: 3.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.